Recombinant Human HLA G His Protein

SDS-Page: Recombinant Human HLA G Protein [NBP2-61457] - 15% SDS-Page (3ug)

• Reactivity: Hu
• Applications: PAGE
• Concentration: 0.25 mg/ml

Recombinant Human HLA G His Protein Summary

• Description: A recombinant protein with a N-terminalHis-tag and corresponding to the amino acids 25-308 of Human HLA G.
  
  

  Source: E.coli

  Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MGSHMGSHSM RYFSAAVSRP GRGEPRFIAM GYVDDTQFVR FDSDSACPRM EPRAPWVEQE GPEYWEEETR NTKAHAQTDR MNLQTLRGYY NQSEASSHTL QWMIGCDLGS DGRLLRGYEQ YAYDGKDYLA LNEDLRSWTA ADTAAQISKR KCEAANVAEQ RRAYLEGTCV EWLHRYLENG KEMLQRADPP KTHVTHHPVF DYEATLRCWA LGFYPAEIIL TWQRDGEDQT QDVELVETRP AGDGTFQKWA AVVVPSGEEQ RYTCHVQHEG LPEPLMLRWK QSSLPTIPI

• Source: E. coli
• Protein/Peptide Type: Recombinant Protein
• Gene: HLA-G
• Purity: >90%, by SDS-PAGE

Applications/Dilutions

• Dilutions:
  • SDS-Page
• Theoretical MW: 35.3 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.4), 20% Glycerol
• Preservative: No Preservative
• Concentration: 0.25 mg/ml
• Purity: >90%, by SDS-PAGE

Alternate Names for Recombinant Human HLA G His Protein

• b2 microglobulin
• HLA class I histocompatibility antigen, alpha chain G
• HLA class I molecule
• HLA G antigen
• HLA G
• HLA-6.0
• HLA-G histocompatibility antigen, class I, G
• HLAG
• HLA-G
• major histocompatibility complex, class I, G
• MHC Class I Antigen G
• MHC class Ib antigen
• MHC-G
• mutant MHC class I antigen
• mutant MHC class Ib antigen
• sHLA-G
• Soluble HLA class I histocompatibility antigen, alpha chain G

Background

Human leukocyte antigen (HLA)-G is a non-classical major histocompatibility complex (MHC) class I gene belonging to the HLA class I family. The HLA class I family is subdivided into the classical (HLA-Ia) antigens comprised of HLA-A, -B, and -C molecules and the nonclassical (HLA-Ib) group including the HLA-E, -F, and -G molecules. Seven different splice variants of HLA-G have been observed including four membrane isoforms (HLA-G1, HLA-G2, HLA-G3, and HLA-G4) and three soluble isoforms (HLA-G5, HLA-G6 and HLA-G7). Proteolytic processing of HLA-G1 by metalloproteinases (MMPs) such as MMP-2 produces the soluble isoform, shedding HLA-G1. The HLA-G1 and HLA-G5 isoforms share a similar confirmation to the classical MHC class I protein, consisting of three extracellular domains including alpha1, alpha2, and alpha3 associated with Beta-2-microglobulin (B2M). Other HLA-G variants are shorter, missing one or two of the globular domains and are not bound to B2M. HLA-G receptors include KIR2DL4 (CD158d), with the highest affinity for ILT2 (LILRB1, CD85j) and ILT4 (LILRB2, CD85d) (1,2).

Discovered in cytotrophoblasts, HLA-G is involved in fetal maternal immune tolerance and some studies have linked its downregulation with severe preeclampsia (3). HLA-G mediated immune suppression works by impeding cell proliferation, differentiation, cytotoxicity, cytokine secretion and chemotaxis; and activation of regulatory cells and MDSCs or M2 type macrophage. HLA-G is constitutively expressed in immune-privileged sites such as pancreatic islets, mesenchymal stem cells (MSCs) and the cornea. Upregulation of HLA-G occurs in pathological states including cancer, allo-transplantations, viral infections, autoimmune and inflammatory diseases (4). In cancer, HLA-G expression is induced by hypoxia and has been correlated with advanced tumor stage, tumor metastasis, and poor therapeutic response and survival. HLA-G is an attractive tumor associated-antigen (TAA) for immunotherapy and is considered a major immune checkpoint (ICP).

References

1. Loustau, M., Anna, F., Drean, R., Lecomte, M., Langlade-Demoyen, P., & Caumartin, J. (2020). HLA-G Neo-Expression on Tumors. Front Immunol, 11:1685. PMID: 32922387

2. Lin A, Yan WH. (2018) Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges. Front Immunol. 9:2164. PMID: 30319626

3. Djurisic S, Hviid TV. (2014) HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia. Front Immunol. 5:652. PMID: 25566263

4. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. (2001) Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A. 98(21):12150-12155. PMID: 11572934

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Publications for HLA G Recombinant Protein (NBP2-61457)(1)

Publication using NBP2-61457

• Li G, Kryczek I, Nam J et al. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy Nature cell biology 2021-05-01 [PMID: 33958760]

Bioinformatics

• Gene Symbol: HLA-G